These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 32775459)

  • 21. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy.
    Scattoni V; Lazzeri M; Lughezzani G; De Luca S; Passera R; Bollito E; Randone D; Abdollah F; Capitanio U; Larcher A; Lista G; Gadda GM; Bini V; Montorsi F; Guazzoni G
    J Urol; 2013 Aug; 190(2):496-501. PubMed ID: 23466239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng/mL.
    Ng CF; Chiu PK; Lam NY; Lam HC; Lee KW; Hou SS
    Int Urol Nephrol; 2014 Apr; 46(4):711-7. PubMed ID: 24136184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.
    Perdonà S; Bruzzese D; Ferro M; Autorino R; Marino A; Mazzarella C; Perruolo G; Longo M; Spinelli R; Di Lorenzo G; Oliva A; De Sio M; Damiano R; Altieri V; Terracciano D
    Prostate; 2013 Feb; 73(3):227-35. PubMed ID: 22821756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measurement of serum isoform [-2]proPSA derivatives shows superior accuracy to magnetic resonance imaging in the diagnosis of prostate cancer in patients with a total prostate-specific antigen level of 2-10 ng/ml.
    Furuya K; Kawahara T; Narahara M; Tokita T; Fukui S; Imano M; Mitome T; Ito Y; Izumi K; Osaka K; Yokomizo Y; Hayashi N; Hasumi H; Nawata S; Kawano T; Yao M; Uemura H
    Scand J Urol; 2017 Aug; 51(4):251-257. PubMed ID: 28351193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate volume does not provide additional predictive value to prostate health index for prostate cancer or clinically significant prostate cancer: results from a multicenter study in China.
    Huang D; Wu YS; Ye DW; Qi J; Liu F; Helfand BT; Zheng SL; Ding Q; Xu DF; Na R; Xu JF; Sun YH
    Asian J Androl; 2020; 22(5):539-543. PubMed ID: 31929198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of the Prostate Health Index and Density in 3 Outpatient Centers to Avoid Unnecessary Prostate Biopsies.
    Schulze A; Christoph F; Sachs M; Schroeder J; Stephan C; Schostak M; Koenig F
    Urol Int; 2020; 104(3-4):181-186. PubMed ID: 32224611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study.
    Fossati N; Buffi NM; Haese A; Stephan C; Larcher A; McNicholas T; de la Taille A; Freschi M; Lughezzani G; Abrate A; Bini V; Palou Redorta J; Graefen M; Guazzoni G; Lazzeri M
    Eur Urol; 2015 Jul; 68(1):132-8. PubMed ID: 25139197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer.
    Huang YQ; Sun T; Zhong WD; Wu CL
    Am J Clin Exp Urol; 2014; 2(4):343-50. PubMed ID: 25606581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparisons of the diagnostic accuracy across prostate health index, prostate health index density, and percentage free prostate-specific antigen for clinically significant prostate cancer: a prospective diagnostic study.
    Wu B; Shao Y; Lin X; Hasi C; Jia W; Wang D; Cao X
    Transl Androl Urol; 2023 Mar; 12(3):425-432. PubMed ID: 37032752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml.
    Ferro M; Bruzzese D; Perdonà S; Marino A; Mazzarella C; Perruolo G; D'Esposito V; Cosimato V; Buonerba C; Di Lorenzo G; Musi G; De Cobelli O; Chun FK; Terracciano D
    PLoS One; 2013; 8(7):e67687. PubMed ID: 23861782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10-20 ng/mL and normal digital rectal examination.
    Chiu PK; Teoh JY; Lee WM; Yee CH; Chan ES; Hou SM; Ng CF
    Investig Clin Urol; 2016 Sep; 57(5):336-42. PubMed ID: 27617315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic performance of prostate health index (PHI) in predicting prostate cancer on prostate biopsy.
    Othman H; Abu Yamin AH; Md Isa N; Bahadzor B; Syed Zakaria SZ
    Malays J Pathol; 2020 Aug; 42(2):209-214. PubMed ID: 32860373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical performance of the Prostate Health Index (PHI) for the prediction of prostate cancer in obese men: data from the PROMEtheuS project, a multicentre European prospective study.
    Abrate A; Lazzeri M; Lughezzani G; Buffi N; Bini V; Haese A; de la Taille A; McNicholas T; Redorta JP; Gadda GM; Lista G; Kinzikeeva E; Fossati N; Larcher A; Dell'Oglio P; Mistretta F; Freschi M; Guazzoni G
    BJU Int; 2015 Apr; 115(4):537-45. PubMed ID: 25130593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate health index density predicts aggressive pathological outcomes after radical prostatectomy in Taiwanese patients.
    Huang YP; Lin TP; Cheng WM; Wei TC; Huang IS; Fan YH; Lin CC; Huang EYH; Chung HJ; Kuo JY; Wu HHH; Lu SH; Chang YH; Lin ATL; Huang WJS
    J Chin Med Assoc; 2019 Nov; 82(11):835-839. PubMed ID: 31425303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Value of the Prostate Health Index and Derived Indexes in the Diagnosis of Prostate Cancer with PI-RADS-3 Lesions.
    Cui Y; Zhao J; Sun Y
    Urol Int; 2023; 107(10-12):959-964. PubMed ID: 38011845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate health index (PHI) as an accurate prostate cancer predictor.
    Yáñez-Castillo YM; Melgarejo-Segura MT; Funes-Padilla C; Folgueral-Corral ME; García-Larios JV; Arrabal-Polo MA; De Haro Muñoz T; Arrabal-Martín M
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9329-9335. PubMed ID: 37204514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate Health Index density improves detection of clinically significant prostate cancer.
    Tosoian JJ; Druskin SC; Andreas D; Mullane P; Chappidi M; Joo S; Ghabili K; Mamawala M; Agostino J; Carter HB; Partin AW; Sokoll LJ; Ross AE
    BJU Int; 2017 Dec; 120(6):793-798. PubMed ID: 28058757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical value of serum isoform [-2] proprostate-specific antigen and its derivatives in predicting aggressive prostate cancer].
    Sun KX; Yan CL; Li ZY; Liu P; Zhang W; He Q
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):234-239. PubMed ID: 32306004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PHI density prospectively improves prostate cancer detection.
    Stephan C; Jung K; Lein M; Rochow H; Friedersdorff F; Maxeiner A
    World J Urol; 2021 Sep; 39(9):3273-3279. PubMed ID: 33471165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic accuracy of prostate health index to identify aggressive prostate cancer. An Institutional validation study.
    Morote J; Celma A; Planas J; Placer J; Ferrer R; de Torres I; Pacciuci R; Olivan M
    Actas Urol Esp; 2016; 40(6):378-85. PubMed ID: 26923032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.